Research from the University of Illinois at Chicago has found that some of the genes affected by alcohol and inflammation
Continue reading »
Home » Health Problems »
New approach to immunotherapy leads to complete response in breast cancer patient
A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression
Continue reading »
Porn viewers prefer women’s pleasure over violence: study
Is mainstream pornography becoming more and more violent? And if so, what’s driving the trend. In our newly published study
Continue reading »
Study links neighborhood factors, breast cancer rates in African-American women
Neighborhood characteristics such as racial composition and poverty rates are associated with increased risks of late-stage breast cancer diagnoses and
Continue reading »
In MS, disintegrating brain lesions may indicate the disease is getting worse
For decades, clinicians treating multiple sclerosis (MS) have interpreted the appearance of new or expanding brain lesions on magnetic resonance
Continue reading »
Why hip fractures in the elderly are often a death sentence
The news an elderly relative has broken a hip tends to sound alarm bells, perhaps more than breaking another bone
Continue reading »
California on front line as STDs run rampant in US
A billboard on Sunset Boulevard in Hollywood screams out a stark warning: “drug-resistant gonorrhea alert!” The words are set against
Continue reading »
Increase in lifestyle-related cancers over past decade spotlights need for prevention
Lifestyle-related cancers, such as lung, colorectal, and skin cancers, have increased globally over the past decade, according to the most
Continue reading »
Targeted cancer treatments far outperform traditional methods
Cancer treatments that attack tumors based on their individual genetic traits—not their location in the body—far outperform traditional methods, extending
Continue reading »
ALEX trial results show alectinib further outpacing crizotinib in ALK+ NSCLC
Updated results of the global phase III ALEX trial comparing alectinib with crizotinib as first-line treatment against ALK-positive non-small cell
Continue reading »